Prognostic value of CD44 variant exon 6 expression in non-small cell lung cancer: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 16, 2014, Pages 6761-6766

  Zhao, Shuang ^a   He, Jin Lan ^a   Qiu, Zhi Xin ^a   Chen, Nian Yong ^a   Luo, Zhuang ^a,b   Chen, Bo Jiang ^a   Li, Wei Min ^a  

^a SICHUAN UNIVERSITY   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

CD44 variant exon 6; Meta analysis; Non small cell lung cancer; Overall survival

Indexed keywords

CD44 PROTEIN, HUMAN; HERMES ANTIGEN; ISOPROTEIN; TUMOR MARKER;

ADENOCARCINOMA; BIOSYNTHESIS; DISEASE COURSE; FEMALE; GENETICS; HUMAN; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; META ANALYSIS; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR INVASION;

ADENOCARCINOMA; ANTIGENS, CD44; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; PROGNOSIS; PROTEIN ISOFORMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906837472     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.16.6761     Document Type: Article

References (37)

1. Afify AM, Tate S, Durbin-Johnson B, et al (2011). Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors. Int J Biol Markers, 26, 50-7.
2. Coradini D, Zorzet S, Rossin R, et al (2004). Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res, 10, 4822-30.
3. Chen P, Huang HF, Lu R, et al (2012). Prognostic significance of CD44v6/v7 in acute promyelocytic leukemia. Asian Pac J Cancer Prev, 13, 3791-4.
4. Deng Z, Niu G, Cai L, et al (2013). The prognostic significance of CD44V6, CDH11, and β-Catenin expression in patients with osteosarcoma. Biomed Res Int, 2013, 496193.
5. Fan CW, Wen L, Qiang ZD, et al (2012). Prognostic significance of relevant markers of cancer stem cells in colorectal cancer-a meta analysis. Hepatogastroenterology, 59, 1421-7.
6. Fukuse T, Hirata T, Naiki H, et al (1999). Expression of proliferating cell nuclear antigen and CD44 variant isoforms in the primary and metastatic sites of nonsmall cell lung carcinoma with intrapulmonary metastases. Cancer, 86, 1174-81.
7. Gunthert U, Hofmann M, Rudy W, et al (1991). A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 65, 13-24.
8. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
9. Higgins JPT, Green S (2011). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. Available:www.cochrane-handbook.org. [updated March 2011]
10. Hirata T, Fukuse T, Naiki H, et al (1998). Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic Factor. Cancer Res, 58, 1108-10.
11. Jijiwa M, Demir H, Gupta S, et al (2011). CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. Plos One, 6, 24217.
12. Jung T, Gross W, Zoller M (2011). CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem, 286, 15862-74.
13. Kunlabut K, Vaeteewoottacharn K, Wongkham C, et al (2012). Aberrant expression of CD44 in bile duct cancer correlates with poor prognosis. Asian Pac J Cancer Prev, 13, 95-9.
14. Kaufmann M, Heider KH, Sinn HP, et al (1995). CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet, 345, 615-9.
15. Lau J, Ioannidis JP, Schmid CH (1997). Quantitative synthesis in systematic reviews. Ann Intern Med, 127, 820-6.
16. Lee LN, Kuo SH, Lee YC, et al (2005). CD44 splicing pattern is associated with disease progression in pulmonary adenocarcinoma. J Formos Med Assoc, 104, 541-8.
17. Liu YJ, Yan PS, Li J, et al (2005). Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. World J Gastroenterol, 11, 6601-6.
18. Mayer B, Jauch KW, Gunthert U, et al (1993). De-novo expression of CD44 and survival in gastric cancer. Lancet, 342, 1019-22.
19. Mackay CR, Terpe HJ, Stauder R, et al (1994). Expression and modulation of CD44 variant isoforms in humans. J Cell Biol, 124, 71-82.
20. Macaskill P, Walter SD, Irwig L (2001). A comparison of methods to detect publication bias in meta-analysis. Stat Med, 20, 641-54.
21. Marhaba R, Bourouba M, Zoller M (2005). CD44v6 promotes proliferation by persisting activation of MAP kinases. Cell Signal, 17, 961-73.
22. Miyoshi T, Kondo K, Hino N, et al (1997). The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer. Clin Cancer Res, 3, 1289-97.
23. Mei TH, Zhang GR, Ma Y (2004). The expression of vascular endothelial growth factor, CD44v6 in non-small cell lung carcinoma. Zhonghua Wai Ke Za Zhi, 42, 647-50.
24. Naor D, Sionov RV, Ish-Shalom D (1997). CD44: structure, function, and association with the malignant process. Adv Cancer Res, 71, 241-319.
25. Nguyen VN, Mirejovsky T, Melinova L, et al (2000). CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance. Neoplasma, 47, 400-8.
26. Omran OM, Ata HS (2012). CD44s and CD44v6 in diagnosis and prognosis of human bladder cancer. Ultrastruct Pathol, 36, 145-52.
27. Ramasami S, Kerr KM, Chapman AD, et al (2000). Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma. J Pathol, 192, 427-32.
28. Sun BS, Li Y, Zhang ZF, et al (2013). Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg, 96, 1943-51.
29. Su CY, Li YS, Han Y, et al (2014). Correlation between expression of cell adhesion molecules CD44v6 and E-cadherin and lymphatic metastasis in non- small cell lung cancer. Asian Pac J Cancer Prev, 15, 2221-4.
30. Situ D, Long H, Lin P, et al (2010). Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma. J Cancer Res, 136, 1213-9.
31. Shi J, Zhou Z, Di W, et al (2013). Correlation of CD44v6 expression with ovarian cancer progression and recurrence. BMC Cancer, 13, 182.
32. Spaford MF, Koeppe J, Pan Z, et al (1996). Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell
33. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.
34. Weng MX, Wu CH, Yang XP (2008). Expression and significance of E-cadherin, CD44v6, and proliferating cell nuclear antigen in non-small cell lung cancer. Ai Zheng, 27, 191-5.
35. Wu Q, Jiang Y, Min J, et al (2005). Expression of CD44v6 and its prognostic significance in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi, 8, 215-8.
36. Wielenga VJ, Heider KH, Offerhaus GJ, et al (1993). Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res, 53, 4754-6.
37. Zhang L, Meng L, Wang L, et al (2004). The clinical significance of detection of vascular endothelial growth factor and CD44v6 expression in human non-small cell lung cancer. Zhongguo Fei Ai Za Zhi, 7, 427-30.